Longevity & AgingOral Alzheimer's Drug Buntanetap Shows Cognitive Gains and Biomarker Shifts in Phase 2/3 Trial
Annovis Bio has published peer-reviewed results for buntanetap, an oral Alzheimer's drug, in Nature NPJ Dementia. The 12-week randomized controlled trial tested three doses in 351 patients with mild to moderate Alzheimer's disease. The 30 mg dose produced statistically significant cognitive improvements — measured by the ADAS-Cog11 scale — specifically in patients with confirmed pTau217 biomarker positivity and mild disease. Beyond cognition, the drug reduced levels of toxic proteins like TDP-43 and tau, and lowered neuroinflammation markers including IL-6 and IFN-γ. Neurofilament light chain, a marker of nerve damage, also decreased. The drug was well tolerated across all doses, ages, sexes, and genetic risk profiles including ApoE4 carriers. A larger pivotal Phase 3 trial is now 80% enrolled, targeting early Alzheimer's patients over 6 and 18 months.
